Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lilly Leadership Falls To Lechleiter In ’08 As Taurel Resigns As CEO

Executive Summary

The appointment of Lilly President and Chief Operating Officer John Lechleiter to CEO should be a smooth transition in early 2008 when longtime chief exec Sidney Taurel retires

You may also be interested in...



Lilly’s Lechleiter to chairman

Lilly CEO John Lechleiter assumes the added role of chairman of the board effective Jan. 1, 2009, succeeding Sidney Taurel, who will become chairman emeritus. The move completes the transition in the company's top management. Lechleiter succeeded Taurel as CEO in April (1"The Pink Sheet," Jan. 7, 2008, p. 10). Taurel has served as Lilly's chairman since 1999, following his appointment as CEO in 1998. Lechleiter, a 28-year veteran of the company, was appointed president and chief operating officer in 2005

Lilly’s Lechleiter to chairman

Lilly CEO John Lechleiter assumes the added role of chairman of the board effective Jan. 1, 2009, succeeding Sidney Taurel, who will become chairman emeritus. The move completes the transition in the company's top management. Lechleiter succeeded Taurel as CEO in April (1"The Pink Sheet," Jan. 7, 2008, p. 10). Taurel has served as Lilly's chairman since 1999, following his appointment as CEO in 1998. Lechleiter, a 28-year veteran of the company, was appointed president and chief operating officer in 2005

Altus Names Gemayel CEO; Milligan Becomes Gilead President

Presidents & CEOs

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS049155

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel